JP2010537623A5 - - Google Patents

Download PDF

Info

Publication number
JP2010537623A5
JP2010537623A5 JP2010500022A JP2010500022A JP2010537623A5 JP 2010537623 A5 JP2010537623 A5 JP 2010537623A5 JP 2010500022 A JP2010500022 A JP 2010500022A JP 2010500022 A JP2010500022 A JP 2010500022A JP 2010537623 A5 JP2010537623 A5 JP 2010537623A5
Authority
JP
Japan
Prior art keywords
androgen
polypeptide
binding
polypeptide according
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010500022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010537623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2008/000424 external-priority patent/WO2008116262A1/en
Publication of JP2010537623A publication Critical patent/JP2010537623A/ja
Publication of JP2010537623A5 publication Critical patent/JP2010537623A5/ja
Pending legal-status Critical Current

Links

JP2010500022A 2007-03-27 2008-03-26 前立腺癌を治療する方法及び組成物 Pending JP2010537623A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2007901628A AU2007901628A0 (en) 2007-03-27 Methods and compositions for treating prostate cancer
US94528207P 2007-06-20 2007-06-20
US99063707P 2007-11-28 2007-11-28
PCT/AU2008/000424 WO2008116262A1 (en) 2007-03-27 2008-03-26 Methods and compositions for treating prostate cancer

Publications (2)

Publication Number Publication Date
JP2010537623A JP2010537623A (ja) 2010-12-09
JP2010537623A5 true JP2010537623A5 (enExample) 2011-05-12

Family

ID=39787967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010500022A Pending JP2010537623A (ja) 2007-03-27 2008-03-26 前立腺癌を治療する方法及び組成物

Country Status (6)

Country Link
US (2) US20100092477A1 (enExample)
EP (1) EP2137213A4 (enExample)
JP (1) JP2010537623A (enExample)
AU (1) AU2008232311A1 (enExample)
CA (1) CA2681917A1 (enExample)
WO (1) WO2008116262A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291086A1 (en) * 2007-09-11 2010-11-18 Christopher Hovens Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
CA2733506A1 (en) * 2008-08-08 2010-02-11 Christopher Hovens Biological applications of steroid binding domains
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
KR101183615B1 (ko) * 2011-12-28 2012-09-17 재단법인 경기과학기술진흥원 Ｗｎｔ에 결합하는 신규한 재조합 단백질
WO2014152640A1 (en) * 2013-03-15 2014-09-25 Invivis Pharmaceuticals Inc. Assay for predictive biomarkers of anti-androgen efficacy
HUE047732T2 (hu) * 2015-05-18 2020-05-28 Nerre Therapeutics Ltd NK-1/NK-3 receptor antagonista vértolulások kezeléséhez
CN120605334B (zh) * 2025-08-11 2025-11-04 核工业总医院 Fbxo2在治疗前列腺癌中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307030B1 (en) * 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH04356427A (ja) * 1991-02-26 1992-12-10 Keisuke Hirasawa 免疫賦活剤
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6117639A (en) * 1998-08-31 2000-09-12 Vertex Pharmaceuticals Incorporated Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity
EA010594B1 (ru) * 2001-05-24 2008-10-30 Займодженетикс, Инк. Слитые белки taci-иммуноглобулина
EP1673395A1 (en) * 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US20060246511A1 (en) * 2005-04-27 2006-11-02 B&C Biotech Methods of determining levels of steroid fractions utilizing SHBG calculations
GB0614568D0 (en) * 2006-07-21 2006-08-30 Haptogen Ltd Anti-testosterone antibodies

Similar Documents

Publication Publication Date Title
NZ597694A (en) Anti-IGF antibodies
EP4527403A3 (en) Dual function proteins and pharmaceutical composition comprising same
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
PL2331118T3 (pl) Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
EA201000785A1 (ru) Композиции для доставки в легкие
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
MX356295B (es) Análogos de péptido de la hormona de estimulación de alfa-melanocito.
EA201390813A1 (ru) Антитела и их применение
GEP20115324B (en) Tweak binding antibodies
WO2010142952A3 (en) Antibodies
GB201201314D0 (en) Composition
MX344559B (es) Compuestos de hormona de crecimiento humana recombinante unidos al peg.
TNSN07020A1 (en) Her2 antibody composition
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
JP2015526391A5 (enExample)
EA201291234A1 (ru) Аналоги глюкагона
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2010053546A3 (en) Crf1 receptor compounds
WO2008142303A3 (fr) Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
WO2010132370A3 (en) Soluble tlt-1 for the treatment and diagnosis of sepsis
WO2009138186A3 (de) SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN
EP2664625A3 (en) Blood-brain barrier permeable peptide compositions